<?xml version='1.0' encoding='utf-8'?>
<document id="24019224"><sentence text="Acetaminophen modulates P-glycoprotein functional expression at the blood-brain barrier by a constitutive androstane receptor-dependent mechanism."><entity charOffset="0-13" id="DDI-PubMed.24019224.s1.e0" text="Acetaminophen" /><entity charOffset="106-116" id="DDI-PubMed.24019224.s1.e1" text="androstane" /><pair ddi="false" e1="DDI-PubMed.24019224.s1.e0" e2="DDI-PubMed.24019224.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24019224.s1.e0" e2="DDI-PubMed.24019224.s1.e1" /></sentence><sentence text="Effective pharmacologic treatment of pain with opioids requires that these drugs attain efficacious concentrations in the central nervous system (CNS)" /><sentence text=" A primary determinant of CNS drug permeation is P-glycoprotein (P-gp), an endogenous blood-brain barrier (BBB) efflux transporter that is involved in brain-to-blood transport of opioid analgesics (i" /><sentence text="e" /><sentence text=", morphine)"><entity charOffset="2-10" id="DDI-PubMed.24019224.s5.e0" text="morphine" /></sentence><sentence text=" Recently, the nuclear receptor constitutive androstane receptor (CAR) has been identified as a regulator of P-gp functional expression at the BBB"><entity charOffset="45-55" id="DDI-PubMed.24019224.s6.e0" text="androstane" /></sentence><sentence text=" This is critical to pharmacotherapy of pain/inflammation, as patients are often administered acetaminophen (APAP), a CAR-activating ligand, in conjunction with an opioid"><entity charOffset="94-107" id="DDI-PubMed.24019224.s7.e0" text="acetaminophen" /><entity charOffset="109-113" id="DDI-PubMed.24019224.s7.e1" text="APAP" /><entity charOffset="164-170" id="DDI-PubMed.24019224.s7.e2" text="opioid" /><pair ddi="false" e1="DDI-PubMed.24019224.s7.e0" e2="DDI-PubMed.24019224.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24019224.s7.e0" e2="DDI-PubMed.24019224.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24019224.s7.e0" e2="DDI-PubMed.24019224.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24019224.s7.e1" e2="DDI-PubMed.24019224.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24019224.s7.e1" e2="DDI-PubMed.24019224.s7.e2" /></sentence><sentence text=" Our objective was to investigate, in vivo, the role of CAR in regulation of P-gp at the BBB" /><sentence text=" Following APAP treatment, P-gp protein expression was increased up to 1"><entity charOffset="11-16" id="DDI-PubMed.24019224.s9.e0" text="APAP" /></sentence><sentence text="4-1" /><sentence text="6-fold in a concentration-dependent manner" /><sentence text=" Additionally, APAP increased P-gp transport of BODIPY-verapamil in freshly isolated rat brain capillaries"><entity charOffset="15-18" id="DDI-PubMed.24019224.s12.e0" text="APAP" /></sentence><sentence text=" This APAP-induced increase in P-gp expression and activity was attenuated in the presence of CAR pathway inhibitor okadaic acid or transcriptional inhibitor actinomycin D, suggesting P-gp regulation is CAR-dependent"><entity charOffset="116-128" id="DDI-PubMed.24019224.s13.e0" text="okadaic acid" /><entity charOffset="158-171" id="DDI-PubMed.24019224.s13.e1" text="actinomycin D" /><entity charOffset="6-18" id="DDI-PubMed.24019224.s13.e2" text="APAP" /><pair ddi="false" e1="DDI-PubMed.24019224.s13.e2" e2="DDI-PubMed.24019224.s13.e2" /><pair ddi="false" e1="DDI-PubMed.24019224.s13.e2" e2="DDI-PubMed.24019224.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24019224.s13.e2" e2="DDI-PubMed.24019224.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24019224.s13.e0" e2="DDI-PubMed.24019224.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24019224.s13.e0" e2="DDI-PubMed.24019224.s13.e1" /></sentence><sentence text=" Furthermore, morphine brain accumulation was enhanced by P-gp inhibitors in APAP-treated animals, suggesting P-gp-mediated transport"><entity charOffset="14-22" id="DDI-PubMed.24019224.s14.e0" text="morphine" /><entity charOffset="77-84" id="DDI-PubMed.24019224.s14.e1" text="APAP" /><pair ddi="false" e1="DDI-PubMed.24019224.s14.e0" e2="DDI-PubMed.24019224.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24019224.s14.e0" e2="DDI-PubMed.24019224.s14.e1" /></sentence><sentence text=" A warm-water (50Â°C) tail-flick assay revealed a significant decrease in morphine analgesia in animals treated with morphine 3 or 6 hours after APAP treatment, as compared with animals treated concurrently"><entity charOffset="73-81" id="DDI-PubMed.24019224.s15.e0" text="morphine" /><entity charOffset="116-124" id="DDI-PubMed.24019224.s15.e1" text="morphine" /><entity charOffset="144-151" id="DDI-PubMed.24019224.s15.e2" text="APAP" /><pair ddi="false" e1="DDI-PubMed.24019224.s15.e0" e2="DDI-PubMed.24019224.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24019224.s15.e0" e2="DDI-PubMed.24019224.s15.e1" /><pair ddi="false" e1="DDI-PubMed.24019224.s15.e0" e2="DDI-PubMed.24019224.s15.e2" /><pair ddi="false" e1="DDI-PubMed.24019224.s15.e1" e2="DDI-PubMed.24019224.s15.e1" /><pair ddi="false" e1="DDI-PubMed.24019224.s15.e1" e2="DDI-PubMed.24019224.s15.e2" /></sentence><sentence text=" Taken together, our data imply that inclusion of APAP in a pain treatment regimen activates CAR at the BBB and increases P-gp functional expression, a clinically significant drug-drug interaction that modulates opioid analgesic efficacy"><entity charOffset="50-53" id="DDI-PubMed.24019224.s16.e0" text="APAP" /></sentence><sentence text=" " /></document>